Raphael Labs (RL) is a special purpose vehicle incorporated to manage and hold equity in its four subsidiaries. These portfolio companies have varied scientific discovery interests in fields pertaining to the respiratory (both wellness & pharma), cosmeceutical, wound care and R&D sectors.

Raphael Labs is led by Professor Steve Davies Waynflete Professor Emeritus of Chemistry at Oxford University, Professor Rakesh Uppal, Consultant Cardiac Surgeon at Barts Heart Centre and Director of Barts Life Sciences. The team comprises global pharmaceutical executives and entrepreneurs focused in the short-term on preventing airborne viral infections.